Cytisine for Smoking Cessation
2006/08/14 by Jean-François Etter, Jean‐François Etter · 27 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Nicotinic Acetylcholine Receptors Study #Smoking Behavior and Cessation #Vagus Nerve Stimulation Research
paper · doi:10.1001/archinte.166.15.1553
Abstract
BACKGROUND: Cytisine is an agonist of nicotinic receptors; in particular, it binds strongly with alpha(4)beta(2) nicotinic receptors. Cytisine has been used to treat tobacco dependence for 40 years in Eastern Europe. The objective of this study was to review the literature on the effect of cytisine on smoking cessation. METHODS: Review of PubMed, EMBASE, Psychological Abstracts, BIOSIS, Google.com, and Scholar.google.com, using the keywords cytisine, cytisin, zytisin, cytisinum, Tabex, and smoking cessation. Experts and the manufacturer of Tabex were contacted. Placebo-controlled trials were included in a meta-analysis. RESULTS: Ten studies reported the effects of cytisine on smoking cessation, including 4 controlled studies (3 placebo controlled). Nine studies used the Bulgarian drug Tabex, containing 1.5 mg of cytisine per tablet, and one Russian study used buccal films containing either 1.5 mg of cytisine or 0.75 mg of cytisine plus 0.75 mg of anabasine. All studies were published between 1967 and 2005 in Bulgaria, Germany, Poland, and Russia. There were 4404 smokers treated with cytisine and 3518 in control conditions. The pooled odds ratio after 3 to 8 weeks in the 3 placebo-controlled trials (2 were double blind and 1 was randomized) was 1.93 (95% confidence interval, 1.21-3.06). For the 2 placebo-controlled double-blind trials with a longer follow-up, the pooled odds ratio after 3 to 6 months was 1.83 (95% confidence interval, 1.12-2.99). One placebo-controlled double-blind trial had follow-up after 2 years (odds ratio, 1.77; 95% confidence interval, 1.29-2.43). Some adverse effects were reported. Most trials were, however, of poor quality. CONCLUSIONS: Cytisine may be effective for smoking cessation. This fact remained largely unnoticed in the English-language literature.
Cited by
- Cytisine for smoking cessation: A systematic review and meta-analysis
- Rediscovering cytisine: Why the WHO’s decision matters for global public health
- Smoking and suicide: a brief overview. [europepmc]
- Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. [europepmc]
- Visual hallucinations associated with varenicline: a case report. [europepmc]
- Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. [europepmc]
- The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation. [europepmc]
- Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. [europepmc]
- Varenicline for tobacco dependence: panacea or plight? [europepmc]
- Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. [europepmc]
- Variations in binding among several agonists at two stoichiometries of the neuronal, α4β2 nicotinic receptor. [europepmc]
- Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. [europepmc]
- Tobacco control in the Russian Federation--a policy analysis. [europepmc]
- Nicotinic receptor antagonists as treatments for nicotine abuse. [europepmc]
- Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation. [europepmc]
- Examination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation. [europepmc]
- Nicotine receptor partial agonists for smoking cessation. [europepmc]
- Nicotinic Acetylcholine Receptors as Targets for Tobacco Cessation Therapeutics: Cutting-Edge Methodologies to Understand Receptor Assembly and Trafficking. [europepmc]
- Cytisine versus varenicline for smoking cessation for Māori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial. [europepmc]
- Multimodal treatment for smoking cessation with varenicline in alcoholic, methadone-maintained, and psychotic patients: A one-year follow-up. [europepmc]
- A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. [europepmc]
- Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial. [europepmc]
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial). [europepmc]
- Does Smoking Affect OSA? What about Smoking Cessation? [europepmc]
- Nicotine receptor partial agonists for smoking cessation. [europepmc]
- New medications development for smoking cessation. [europepmc]
- Development and Validation of LC-MS/MS Method for Determination of Cytisine in Human Serum and Saliva. [europepmc]
Related